Ipamorelin Compounding Pharmacy: Research-Only vs Medical-Grade Peptides Explained

Is there such a thing as medical-grade ipamorelin?

No. Ipamorelin is not an FDA-approved drug, is not a component of any approved product, and no US Pharmacopeia monograph covers it [1]. The term 'medical grade' suggests a product has met an FDA-recognized standard, and for ipamorelin there is no FDA approval or USP monograph to meet.

The peptide was identified in 1998 and was developed as an investigational drug for postoperative ileus, but that development was reportedly discontinued after disappointing phase 2 results [1][10].

What FDA has decided about compounded ipamorelin

FDA lists ipamorelin acetate in category 2, bulk substances that may present significant safety risks, for compounding by outsourcing facilities. It was added September 29, 2023, and was still on the list on FDA's page dated 04/22/2026 and on the outsourcing-facility version updated March 21, 2025 [2][5]. It is one of the few peptides still in that category [2].

For state-licensed pharmacies and physicians, ipamorelin appears only in FDA's table of nominations that were withdrawn, and in none of the three categories on FDA's list updated May 14, 2026. FDA's category 1 policy, under which it generally takes no action against compounders that meet its conditions, does not apply to it [2][3].

On October 29, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on ipamorelin free base, and the same on ipamorelin acetate. The committee cited a lack of information supporting safety and efficacy for growth hormone deficiency and postoperative ileus [4].

Ipamorelin is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), and no FDA or HHS action allowing its compounding has been identified [9].

What FDA says the safety concerns are

FDA's stated concerns for compounding are possible immunogenicity for certain routes because of aggregation and impurities, unnatural amino acids that complicate characterization, and a study published in the literature that identified serious adverse events including death when ipamorelin was given intravenously to improve gastric motility. FDA said it has not identified safety-related information for other injectable routes [2].

FDA also notes that ipamorelin stimulates the GH and IGF-1 axis, so it may carry the risks listed on approved growth hormone labels — neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism and pancreatitis among them — and, like the approved growth hormone stimulator macimorelin, possibly QT prolongation. FDA found no data showing it would not [1].

What human data exist, and what they show

Ipamorelin is a five-amino-acid synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that releases growth hormone by acting at the ghrelin/GH-secretagogue receptor rather than the GHRH receptor [10]. Most claims about its selectivity come from animal work: in rats and pigs it released growth hormone with potency similar to GHRP-6, and in swine it did not change FSH, LH, prolactin or TSH [10].

The one published phase 2 trial enrolled 117 adults undergoing small or large bowel resection and analyzed 114. Patients received 0.03 mg/kg intravenously twice daily from postoperative day 1 to 7 or discharge, or placebo, in a multicenter, double-blind design. Median time to first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo (p=0.15, not significant), and secondary gastrointestinal recovery endpoints did not differ. Any treatment-emergent adverse event occurred in 87.5% on ipamorelin and 94.8% on placebo [6].

FDA's summary of that trial lists low potassium in 12.5% on ipamorelin versus 3.4% on placebo, insomnia in 10.7% versus 5.2%, high blood sugar at discharge in 14.3% versus 8.6%, and serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications after bowel surgery for colon cancer with anastomotic leak; FDA said it is unclear whether the deaths were related to ipamorelin but that they raise safety concerns [1][6].

A volunteer study gave healthy men single 15-minute intravenous infusions at 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg. Pharmacokinetics were dose-proportional, with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg and steady-state volume of distribution of 0.22 L/kg. Growth hormone rose in a single peak about 0.67 hours after the infusion and fell to negligible levels at every dose. The study measured physiology, not outcomes [7].

Dosing: the numbers that exist, and what they are not

No FDA-approved dose of ipamorelin exists [1]. The only human doses in the published record are intravenous: 0.03 mg/kg twice daily in the ileus trial and single 15-minute infusions of 4.21 to 140.45 nmol/kg in the volunteer study [6][7]. Both are study protocols, not recommended doses [1].

FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [1].

Is a research-only vial safer or riskier?

Neither label confers safety. Compounded sterile preparations carry microbial contamination risk, and published independent testing by FDA, state agencies and others consistently shows that compounded drugs fail to meet specifications at a considerably higher rate than FDA-approved drugs [11]. Compounded drugs are exempt from good manufacturing practice requirements, quality testing is inconsistent, and they are not clinically evaluated for safety or efficacy [11].

Those points apply to any compounded injectable, and ipamorelin is also unapproved. A research-use-only label states a seller's intended use; it is not a quality standard recognized by FDA approval or a USP monograph.

Athletes: WADA names ipamorelin

WADA's 2026 Prohibited List names ipamorelin in S2.2.4, growth hormone secretagogues and their mimetics. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [8]. It is also named in the 2027 List, in force January 1, 2027 [12]. FDA notes that ipamorelin has been found in vials confiscated from athletes [1].

What to check before buying any ipamorelin vial

• FDA status. Ipamorelin is not approved and has no monograph [1].
• Registration. FDA publishes a list of registered outsourcing facilities [13].
• Product documentation. Ask what testing was done on the lot you would receive and who did it. Compounded drug testing is inconsistent, and compounded products fail specifications more often than approved drugs in independent testing [11].